Results 61 to 70 of about 4,708,479 (153)

Fed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian People

open access: yes, 2015
6 páginasThis is a pharmacokinetic study of two formulations containing Bosentan 125 mg, in order to compare the bioavailability between the Test product (Bosentan produced by Tecnoquímicas S.A.
Bustamante C., Villarraga EA., Vargas M.
core   +1 more source

Non-equivalence of antibiotic generic drugs and risk for intensive care patients [PDF]

open access: yes, 2013
Background: The underlying axiom in applying generic drugs is the equivalence of their active ingredient with the (usually more expensive) innovator product, an all-embracing statement with the insidious result that physicians assume that the generic ...
Reshetnykov, Mykhaylo   +4 more
core   +1 more source

Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling. ABSTRACT pH‐dependent drug–drug interactions (DDIs) commonly occur when acid‐reducing agents (ARAs) are co‐administered with weakly basic drugs.
Yuanfang Qin   +6 more
wiley   +1 more source

Bioequivalence Study of Two 50 mg Desvenlafaxine Extended Release Formulations A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Study

open access: yes, 2014
4 páginasThis is a pharmacokinetic study of two formulations containing Desvenlafaxine succinate 50 mg extended release. Its objective was to compare the bioavailability between the Test product (Desvenlafaxine ER produced by Tecnoquímicas S.A., Colombia
Villarraga, E., Vargas, M., Vargas, Jba
core   +1 more source

Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects

open access: yesThe AAPS Journal
Abstract Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome’s set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate release (IR) tablets, modified release (MR) tablets and IR solution.
Kazuko Sagawa   +6 more
openaire   +2 more sources

A Simulation‐Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences

open access: yesClinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Bridging studies are often waived for orphan diseases such as multiple myeloma (MM) due to challenges in conducting clinical trials in small and heterogeneous populations. However, demographic and regional differences between trial participants and Asian populations may influence drug exposure and response.
Minji Kang   +4 more
wiley   +1 more source

Osteoarthritis: Epidemiology, Diagnosis, and Treatment

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Osteoarthritis (OA) is a multifactorial degenerative joint disease and a leading cause of disability worldwide. This graphical abstract summarizes the epidemiology, diagnostic strategies, and therapeutic approaches of OA. OA development is driven by aging, metabolic dysregulation, and mechanical stress, leading to progressive joint degeneration ...
Qin Ru   +7 more
wiley   +1 more source

Review Article - Bioequivalence: Issues and perspectives [PDF]

open access: yes, 2007
The design, performance and evaluation of bioavailability and bioequivalence have evolved over the last two decades. Bioequivalence (BE) means the absence of a greater-than-allowable difference between the systemic bioavailability of a test product and ...
Rani, Shubha
core   +1 more source

Bioequivalence Study of Two Formulations Containing Lurasidone 80 mg Tablets in Healthy Colombian Volunteers

open access: yes, 2016
4 páginasThis is a pharmacokinetic study of two formulations containing Lurasidone 80 mg, with the aim to compare the Bioavailability between the Test product (Lurasidone made by Laboratorios Lafrancol S.A, Colombia) and the Reference product (Latuda ...
Vargas M., Villarraga EA
core   +1 more source

Home - About - Disclaimer - Privacy